Home

AGESA — Deck

AgeSA Hayat ve Emeklilik · AGESA · BIST

Turkey's #1 private pension franchise compounding 63% ROE while the market argues whether 2024–25 was structural or a rate-cycle gift

₺236
Price (17-Apr-2026)
₺42.5B
Market cap
63%
FY25 ROE 14% real after CPI
6.97×
P/E (mgmt TTM) 42% discount to global life
₺402B pension AuM · 18.6% private-sector share · expense ratio 48.5% → 39.2% · 55% nominal BVPS CAGR · Complementary Pension launch due Q2 2026
1 · What this is

Turkey's largest private life-and-pension franchise, piped through Akbank — a levered spread book with a fee engine attached

  • Business model. Three stacked engines on one distribution asset. Private pensions (₺402B AuM, 18.6% private-sector share) earn management fees on a state-matched, 10-year-vested pool. Credit-linked life writes short-tail underwriting margin alongside Akbank loans. And ₺381B of policyholder float sits against only ₺8.6B of equity — 47× leverage that turns the Turkish short rate directly into profit.
  • Competitive position. The moat is distribution and regulatory architecture, not product. Exclusive Akbank bancassurance (Turkey's second-largest private bank, 41% Sabancı-owned) plus the 40/40 Sabancı–Ageas JV delivers the #1 private-sector slot in both pension AuM and Life & PA premium. The only listed private peer, ANHYT, runs pension-heavy with a 48% ROE against AGESA's 63%.
  • What's changed recently. Net investment income scaled from ₺80M in 2020 to ₺3.09B in 2025 as CBRT pushed the policy rate to 47.5%; the business has mechanically shifted from an insurer with a float attached to a float vehicle with an insurance franchise attached. Credit-linked life is now the largest technical engine at ₺5.26B, and Medisa (100% health-insurance subsidiary, ₺1.4B cumulative capital) is the next bolt-on.
Three businesses, one distribution channel, one macro cycle — all anchored to Akbank's branch network and the CBRT policy rate.
2 · Money picture

Book value compounding 55% nominal CAGR over five years while the stock still trades under 7× management earnings

₺24.4B
FY25 GWP +70% YoY, 18× since 2020
₺6.84B
FY25 net profit (mgmt) +72% YoY · ₺5.15B SFRS
39.2%
Expense ratio FY25 48.5% → 39.2% in 5 yrs
204%
Solvency I 2× regulator floor

Expense-ratio compression is the cycle-insensitive leg — every 100bp of further grind on a ₺12.9B technical base adds ₺129M of profit. The fragile leg is the ₺3.09B of net investment income, up 39× since 2020 on a 47.5% policy rate. For the next 12 months to hold: spread income needs to stay above roughly ₺800M per quarter as CBRT cuts, with pension-fee growth absorbing the slack. That shift is what the Q1 2026 print will either validate or break.

3 · Price picture

Uptrend intact but pinned under the ₺256 February all-time high

  • Trend. At ₺236 the stock sits 16.5% above a rising 200-day; the 50-day has held above the 200-day for the full two-year window with no death cross. Up 202.6% over two years on near-linear, earnings-driven repricing — no squeeze footprint, and the largest-volume sessions of 2025–26 were up-days.
  • Relative strength. In lira terms AGESA tripled (100 → 303) while SPY rose about 42%; two-year total return beats ANHYT (+133%), TURSG (+109%) and AKGRT (+10%) by wide margins. Roughly half of the TRY-denominated gain reflects inflation rather than real value creation — real BVPS growth is closer to 14% per year.
  • Key levels. A close through ₺256 (Feb 2026 ATH) clears overhead supply and validates the next leg. A close under ₺202 (the 200-day and early-March low) breaks the uptrend and flips the read to neutral-to-bearish.
Range-bound between a ₺210–217 shelf and the ₺253–256 ceiling while the tape waits for the May earnings print.
4 · Who runs this

Nine-year CEO, two controlling shareholders aligned on cash — but only 2 of 8 directors are independent

  • Ownership. Sabancı Holding 40% + Ageas (Belgium) 40% + 20% free float. The two parents jointly appoint every board seat except the two formal independents, and minority shareholders have no realistic path to block a decision the JV partners agree on. Zero share issuance in five years; an active ₺750M buyback authorisation has deployed only ₺100M in 21 months.
  • Leadership. CEO Fırat Kuruca has run the company since 1 January 2017 — through the Aviva-to-Ageas swap, COVID, the 2023 earthquake and the TAS 29 debate. Since June 2024 he also runs sister-co Aksigorta, consolidating Sabancı's insurance platform under one operator. Board Chair is now Sabri Hakan Binbaşgil, ex-Akbank CEO.
  • Signal. The ₺3.83B 2024 commission paid to Akbank is the governance pressure point — larger than the full-year dividend, 4× the buyback, and roughly as big as net technical profit. It doubled YoY. Akbank is 41% Sabancı-owned, an Akbank executive sits on AGESA's board, and no independent fairness opinion is disclosed on the commission rate.
5 · How it got here

One CEO, one strategy, one brand swap — and a quiet 18× scale-up through 85% CPI

The past: Founded 2007 as AvivaSA, a 50/50 JV between Aksigorta and Aviva plc. Listed on BIST in 2014, with Fırat Kuruca taking the CEO seat on 1 January 2017. Pension leadership among private companies has held continuously since June 2015 — the franchise predates everything else on this page.

The pivot: In May 2021 Aviva sold its 40% stake to Belgium's Ageas for ₺1.2bn; the company rebranded to AgeSA on 1 July 2021. Management kept the strategy but layered a life-insurance pivot on top — Savings Life launched August 2022, the only numerical guidance ever issued (FY22 SFRS ₺850–950M) landed at ₺875M, and the 2023 disinflation shock lit up the float economics.

Today: GWP 18× since 2020 (₺1.3B → ₺24.4B), pension AuM 13× (₺30.5B → ₺402B), solvency strengthened from 145% to 204% even while paying a ₺1.0B dividend and injecting ₺1.4B into the 100%-owned Medisa health subsidiary. The next chapter answers whether the TES (Complementary Pension System) launch — due Q2 2026 — turns AgeSA into a ₺1 trillion asset manager, and whether real growth survives once TRY disinflation strips the nominal flatter.

A single-CEO, single-strategy compounder through macro noise — the inflections came from ownership and M&A, not from strategy resets.
6 · What's happening now

An antitrust probe, a 3× dividend hike, and a health-insurance rollup — all within 90 days of each other

  • Recent event. On 26 February 2026, Turkey's Competition Authority opened a no-poach / labor-information probe into 26 banks, insurers and IT firms — AgeSA named alongside Akbank, Aksigorta and most of Turkey's big banks. Preliminary inquiry cited 'serious and sufficient' evidence but no finding yet; any KAP update is market-moving, and historical Turkish insurance fines have been small versus profit.
  • Market view. Four Buy / zero Sell on Investing.com's consensus at a ₺332.59 12-month target (+41% upside). Alpha Spread sits at ₺287; Morningstar's quant model prints a headline-grabbing ₺883 fair value on high uncertainty. The dispersion is the story — analysts disagree on whether 2024–25 spread income was a one-off or a structural step-change.
  • Off-filing signal. Active LinkedIn hiring is skewed to compliance, internal audit and info-sec at Istanbul HQ — consistent with preparing for tighter regulatory scrutiny and the antitrust file. Medisa went to 100% ownership on 20 December 2024 for ₺157M, and dividend paid 27 March 2026 was ₺1.0B — a 3.3× jump versus FY24 and the highest payout since 2020.
The antitrust file and the Q1 2026 earnings print land in the same four-week window — the market will price the combination, not either in isolation.
7 · What's next

Two earnings prints, a dated pension-system launch, and a live antitrust file — all inside six months

  • Early May 2026 — Q1 2026 earnings. The single cleanest test of the whole debate. Net investment income holding above ₺800M despite CBRT cuts validates the structural-step-change thesis; a drop toward ₺600M with no pension-fee offset hands the bears their one-off-rate-gift framing.
  • 15 May 2026 — AGM and dividend pay. ₺1.0B dividend (3.3× FY24), 2.35% forward yield at spot, highest payout since 2020. Watch for any upgrade to payout policy — with Solvency I at 204% and ROE in the 60s, the regulatory cap, not capital, is the binding constraint.
  • Q2 2026 — TES (Complementary Pension) launch. Per the Presidential Annual Program, Turkey's second-tier pension system with mandatory employer contributions rolls out this window. AgeSA's 18.6% private share, 59,316 corporate relationships and 957k active contracts make it the clearest listed beneficiary — and the launch timing has slipped before, so confirmation itself is the rerating event.
The May print is the data catalyst; the Q2 TES launch is the structural one. Everything else is noise around those two.
8 · For & against

Slight lean for — expense leverage plus TES optionality carry more weight than the rate-cycle reset risk

  • For. 63% ROE at 4.94× P/B implies a 13% earnings yield on equity — a 42% P/E discount to global life peers with three-to-four times their ROE, wider than Turkey-risk, inflation accounting and 20% float can justify together. Real BVPS growth of 14% per year after CPI is still exceptional.
  • For. Expense-ratio compression from 48.5% to 39.2% in five years is the cycle-insensitive leg — it kept working through 85% CPI and survives a disinflation shock. Every 100bp off the ratio on ₺12.9B of technical income is ₺129M of profit.
  • For. TES is a dated, asymmetric catalyst. Q2 2026 launch with mandatory employer contributions lands directly on AgeSA's #1 private-pension share and 59,316 corporate relationships; the market has not priced it because the date has slipped before.
  • Against. ₺8.6B of equity against ₺405B of assets is 47:1 leverage. The ₺3.09B of net investment income (up 39× since 2020) depends on a policy rate CBRT has started cutting. In 2022–23 technical profit went negative even as reported earnings compounded — the engine was carry, not underwriting.
  • Against. Governance is aligned with the two 40% holders, not minorities. ₺3.83B Akbank commission doubled YoY with no independent fairness benchmark, an Akbank director sits on the board, and the 26 Feb 2026 antitrust probe adds a tail risk. Executive pay is 100% cash with zero equity alignment.
  • Against. Headline growth is flattered by the TRY denominator. 'Management Reporting' framing excludes TAS 29 inflation accounting; real BVPS growth is closer to 14% versus a reported 55% CAGR. As CPI normalises, the optical growth rate compresses even if the business is unchanged — and that is when index-level holders tend to reprice.
My view. Narrow edge to the For side, but the margin is thin enough that the Q1 2026 print is the specific data point that flips conviction. Net investment income holding above ₺800M with a sequential pickup in pension fees would validate the structural step-change — a miss would snap back toward the bear case.

Watchlist to re-rate: (1) Q1 2026 net investment income vs the ₺800M bar and the sequential delta in pension-fee revenue; (2) any KAP disclosure on the Rekabet Kurumu antitrust probe; (3) TES launch confirmation and early corporate-AuM read.